Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 4/20 | 0.44 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6351968 | 1.00 | CYP1A2 (0.46) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL6351966 | 1.00 | CYP1A2 (0.46) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| Hydrochloric Acid SCHEMBL9339921 | 0.98 | LMNA (0.46) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| Hydrochloric Acid SCHEMBL9339915 | 0.98 | LMNA (0.46) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| Hydrochloric Acid SCHEMBL9339918 | 0.98 | LMNA (0.46) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL342825 | 0.74 | LMNA (0.54) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL6354585 | 0.72 | CYP1A2 (0.55) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| Hydrochloric Acid SCHEMBL9340197 | 0.71 | LMNA (0.56) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL2353070 | 0.70 | CYP1A2 (0.57) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL6351470 | 0.69 | CYP1A2 (0.52) | CYP1A2MEN1KMT2AGABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | SAEGIS PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | claimed |
| EP-0319482-B1 | Novel substituted propane phosphinic acid compounds | CIBA GEIGY AG (CH) | 1994-05-18 | — | — | EP | claimed |
| EP-0319479-A2 | Substituted propane-phosphinic acid compounds | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | claimed |
| EP-0319482-A2 | Novel substituted propane phosphinic acid compounds | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | claimed |
| US-20050222093-A1 | Methods for restoring cognitive function following systemic stress | PEARLMAN RODNEY | 2005-10-06 | — | — | US | disclosed |
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | SAEGIS PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | disclosed |
| EP-0319482-B1 | Novel substituted propane phosphinic acid compounds | CIBA GEIGY AG (CH) | 1994-05-18 | — | — | EP | disclosed |
| US-5300679-A | Antagonists to 4-aminobutyric acid | CIBA-GEIGY CORPORATION (US) | 1994-04-05 | — | — | US | disclosed |
| US-5190933-A | Treatment of cognitive and memory disorders | CIBA-GEIGY CORPORATION (US) | 1993-03-02 | — | — | US | disclosed |
| US-5064819-A | Antidepressants, anxiolytic agents, GABA antagonists | CIBA-GEIGY CORPORATION (US) | 1991-11-12 | — | — | US | disclosed |
| US-5051524-A | Treatment of a phosphinic acid with an anhydrous protic medium | CIBA-GEIGY CORPORATION (US) | 1991-09-24 | — | — | US | disclosed |
| US-5013863-A | Learning enhancement | CIBA-GEIGY CORPORATION (US) | 1991-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222093-A1 | Methods for restoring cognitive function following systemic stress | CRH, BDNF, CHAT | CYP1A2 3291/4885MEN1 3754/4885KMT2A 3734/4885 |
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | CRH, BDNF, CHAT | CYP1A2 3291/4885MEN1 3754/4885KMT2A 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.